US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voya Infrastructure Industrials and Materials Fund

9.49

-0.7300-7.14%

Post-market: 9.41-0.0800-0.84%16:05 EDT

Volume:171.74K

Turnover:1.68M

Market Cap:182.96M

PE:- -

High:10.11

Open:10.11

Low:9.45

Close:10.22

Loading ...

Overview Company News Filings

AWS Unveils the Next Generation of Amazon SageMaker, Delivering a Unified Platform for Data, Analytics, and AI

New Amazon Q Developer Capabilities Accelerate Large-Scale Transformations of Legacy Workloads

Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology

Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

Press Release: Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Press Release: Voya Equity Closed End Funds Declare Distributions

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

WiSA Technologies, Inc. Files Preliminary Proxy, Advancing Data Vault Asset Purchase

Press Release: WiSA Technologies, Inc. Reports Q3 2024 Results

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Press Release: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

AMD Announces Versal Premium Series Gen 2 Enabling New Levels of System Acceleration to Meet the Demands of Data-Intensive Workloads

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

IDE: Hedge Yourself Against Recession Risks

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Press Release: WiSA Technologies, Inc. to Host Third Quarter 2024 Results Conference Call at 8:00 am Pacific Time | 11:00 am Eastern Time on November 15th

Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IDE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","market":"US","secType":"STK","nameCN":"Voya Infrastructure Industrials and Materials Fund","latestPrice":9.49,"timestamp":1743796800000,"preClose":10.22,"halted":0,"volume":171741,"hourTrading":{"tag":"盘后","latestPrice":9.41,"preClose":9.49,"latestTime":"16:05 EDT","volume":203,"amount":1910.47,"timestamp":1743797110154},"delay":0,"floatShares":0,"shares":19279000,"eps":0,"marketStatus":"Closed","change":-0.73,"latestTime":"04-04 16:00:00 EDT","open":10.11,"high":10.11,"low":9.45,"amount":1676064.9539,"amplitude":0.064579,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.22,"aum":0,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":9.41,"preClose":9.49,"latestTime":"16:05 EDT","volume":203,"amount":1910.47,"timestamp":1743797110154},"volumeRatio":2.37229},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.37229,"shares":19279000,"dividePrice":1.2,"high":10.11,"amplitude":0.064579,"preClose":10.22,"low":9.45,"week52Low":9.45,"pbRate":"--","week52High":11.766,"institutionHeld":0,"latestPrice":9.49,"eps":0,"divideRate":0.126449,"volume":171741,"delay":0,"ttmEps":0,"open":10.11,"prevYearClose":10.15,"prevWeekClose":10.55,"prevMonthClose":10.58,"prevQuarterClose":10.58,"fiveDayClose":10.55,"twentyDayClose":10.4956,"sixtyDayClose":10.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2488922956","title":"AWS Unveils the Next Generation of Amazon SageMaker, Delivering a Unified Platform for Data, Analytics, and AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2488922956","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488922956?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:56","pubTimestamp":1733252160,"startTime":"0","endTime":"0","summary":"AWS expands its widely adopted machine learning service, combining comprehensive data, analytics, and AI capabilities. LAS VEGAS, December 03, 2024----At AWS re:Invent, Amazon Web Services, Inc. , an Amazon.com, Inc. company , today announced the next generation of Amazon SageMaker, unifying the capabilities customers need for fast SQL analytics, petabyte-scale big data processing, data exploration and integration, model development and training, and generative artificial intelligence  into one integrated platform.The new SageMaker Unified Studio makes it easy for customers to find and access data from across their organization and brings together purpose-built AWS analytics, machine learning , and AI capabilities so customers can act on their data using the best tool for the job across all types of common data use cases, assisted by Amazon Q Developer along the way.New zero-ETL integrations with leading Software-as-a-Service  applications make it easy to access data from third-party S","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AtB9eK7OiojqCYAxiQM6Uw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64be89e0275b96a992ce0b854a7aa764","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AtB9eK7OiojqCYAxiQM6Uw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64be89e0275b96a992ce0b854a7aa764"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aws-unveils-next-generation-amazon-185600475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4503","LU0256863902.USD","LU1119994496.HKD","LU1935043536.SGD","ML","SG9999001077.SGD","LU0353189763.USD","LU1823568750.SGD","IE00B1BXHZ80.USD","LU0417517546.SGD","LU0158827781.USD","LU0203201768.USD","LU0980610538.SGD","IE0003U64NQ7.SGD","LU2552382058.USD","AMZN","LU0127658192.USD","LU0080751232.USD","LU0265550946.USD","IE00BKVL7J92.USD","SG9999018857.SGD","IDE","LU0320765059.SGD","LU1989764664.SGD","LU2242649171.HKD","LU0342679015.USD","LU1868836591.USD","LU2552382132.HKD","LU1145028129.USD","LU0308772762.SGD","LU0170899867.USD","IE00BKDWB100.SGD","BK4596","BK4548","LU1815333072.USD","IE00BJLML261.HKD","LU0096364046.USD","LU2265009873.SGD","IE00B1XK9C88.USD","BK4551","LU2236285917.USD","SGXZ51526630.SGD","LU2063271972.USD","LU0056508442.USD","LU0354030438.USD","LU2430703251.USD","LU0672654240.SGD","LU0011850046.USD"],"gpt_icon":1},{"id":"2488924921","title":"New Amazon Q Developer Capabilities Accelerate Large-Scale Transformations of Legacy Workloads","url":"https://stock-news.laohu8.com/highlight/detail?id=2488924921","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488924921?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:27","pubTimestamp":1733250420,"startTime":"0","endTime":"0","summary":"Amazon Q Developer is the first generative AI-powered assistant for large-scale migration and modernization of Windows .NET, VMware, and mainframe workloads, accelerating transformation timelines and reducing costs. Transform VMware workloads to cloud-native architectures, converting on-premises network configurations into AWS equivalents in hours instead of weeks.Accelerate mainframe modernization by streamlining labor-intensive work like code analysis, documentation, planning, and refactoring applications.Many organizations have a large number of legacy applications that often require specialized expertise to operate and are expensive and time-consuming to maintain. While they want to move away from these legacy technologies, modernizing them can take months or years of tedious work. As a result, organizations stall or postpone these projects entirely, so they can prioritize building new applications and experiences. To make these kinds of projects easier, Amazon Q Developer provides","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Pw_ulNR5GzhubBZQ9yE22A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2a85988b99547834fef5c925fbb39593","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Pw_ulNR5GzhubBZQ9yE22A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2a85988b99547834fef5c925fbb39593"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amazon-q-developer-capabilities-accelerate-182700278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250330.USD","LU2491050154.USD","LU2063271972.USD","BK4122","LU1582986433.USD","NET","LU1974910355.USD","IE00B5949003.HKD","LU1236620750.USD","HCM","LU0820562030.AUD","LU0211327993.USD","LU1582987597.SGD","LU0640476718.USD","LU1670628061.USD","LU0345770308.USD","LU0320765059.SGD","LU0689626769.HKD","IE00BDCRKT87.USD","LU1712237335.SGD","LU0957791311.USD","BK4116","IDE","SG9999001424.SGD","AMZN","LU1221951129.SGD","LU0323240290.USD","IE00BQXX3C00.GBP","IE0034235295.USD","LU0056508442.USD","LU1236620834.HKD","LU1791710582.SGD","LU2065171311.SGD","MSFT","AAQC","LU1267930573.SGD","LU1914381329.SGD","IE00B7KXQ091.USD","LU2404859667.USD","LU1244550494.USD","BK4007","LU0912757837.SGD","LU1935043023.USD","LU2041044095.USD","LU2552382058.USD","LU0889566641.SGD","LU1670711123.USD","LU1235294995.USD"],"gpt_icon":1},{"id":"2486067756","title":"Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2486067756","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486067756?lang=en_us&edition=fundamental","pubTime":"2024-11-26 07:20","pubTimestamp":1732576800,"startTime":"0","endTime":"0","summary":"GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB  XVIVO's innovative heart technology is currently under investigation in the US clinical trial \"PRESERVE: A Prospective, Multi-center, Single-Arm, Open-Label Study of Hearts Transplanted after Non-Ischemic Heart PRESERVation from Extended Donors.\" This marks the enrollment completion of the Investigational Device Exemption  trial which was intended to enroll patients at an ambitious pace of 18 months, but was instead completed in 13 months - 5 months ahead of schedule. To date, 141 patients have undergone transplantation with the XVIVO heart technology at 14 leading heart transplant hospitals in the US. The next milestone will be one year follow-up, where patient outcomes will be collected and monitored before the data is analyzed and presented to the US Food & Drug Administration  via the Pre-Market Approval  process.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qiTeWLVv36_3LPJrPoWUTg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/1129bcc4fb3a617f29af1d2b235bb2c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qiTeWLVv36_3LPJrPoWUTg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/1129bcc4fb3a617f29af1d2b235bb2c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enrollment-completed-five-months-early-232000116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","XVIPF","HOPE","BK4211","IDE","XVIPY"],"gpt_icon":0},{"id":"2486874480","title":"Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486874480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486874480?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:15","pubTimestamp":1732544100,"startTime":"0","endTime":"0","summary":"WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial. SOUTH JORDAN, Utah, Nov. 25, 2024  -- Merit Medical Systems, Inc. , a global leader of healthcare technology, today announced positive six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy  pivotal trial. The data were presented at the 51st annual VEITHsymposium during the Novel Technologies in Hemodialysis Access session.An AVG is a synthetic tube that is used for long-term access to blood vessels for patients undergoing hemodialysis. However, over time, the graft may become narrow or blocked, resulting in potentially life-threatening consequences. Merit’s WRAPSODY Cell-Impermeable Endoprosthesis is designed to restore and extend vessel access  in hemodialysis patients, which is critical for patient survival.“At Merit, we remain committed to continued collaboration with our physician partners to improve care for hemodialysis pati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PIg6KN.CbfP0DzFUtg2Fng--~B/aD0yNDI7dz0xODAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2a69502e94a5e02dae847a38a8b4b18f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PIg6KN.CbfP0DzFUtg2Fng--~B/aD0yNDI7dz0xODAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2a69502e94a5e02dae847a38a8b4b18f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merit-medical-wrapsody-wave-trial-141500573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234572021.USD","LU1066053197.SGD","LU1280957306.USD","LU1162221912.USD","IDE","LU0124676726.USD","LU0566484027.USD","LU0868494617.USD","PG","BK4539","SG9999001440.SGD","IE00B3T34201.USD","BK4018","MMSI","BK4581","BK4133","SG9999015358.SGD","BK4585","BK4534","LU0061475181.USD","LU0094547139.USD","LU1868836757.USD","SG9999015341.SGD","IE00BWXC8680.SGD","LU1868837300.USD","LU2242646821.SGD","LU1066051498.USD","SG9999014542.SGD","LU0096364046.USD","LU1430594728.SGD","SG9999002224.SGD","BK4198","LU0320765646.SGD","IE00BLSP4452.SGD","WAVE","SG9999014559.SGD","SG9999002232.USD","SG9999014567.USD","LU1585245621.USD","LU2552382132.HKD","SG9999014575.USD","LU2552382215.SGD","IE000M9KFDE8.USD","LU0640476718.USD","LU0237698245.USD","BK4588","BK4550","LU1929549753.HKD"],"gpt_icon":1},{"id":"2484290356","title":"Press Release: Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2484290356","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484290356?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:00","pubTimestamp":1732050000,"startTime":"0","endTime":"0","summary":"- Alpha DaRT accepted into the prestigious Total Product Life Cycle Advisory Program  of the FDA, to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme  -. - First patient treated in Recurrent Lung Cancer study in Israel, which will assess the safety and feasibility of delivering Alpha DaRT sources into the lung using an endobronchial ultrasound procedure -. - FDA approval of an Investigational Device Exemption  application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma  in immunocompromised patients using the Alpha DaRT -. JERUSALEM, Nov. 19, 2024  -- Alpha Tau Medical Ltd.  , the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , reported third quarter 2024 financial results and provided a corporate update.including the rate of successful source placement and any","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","LU0321505439.SGD","BK4588","IDE","DRTS","BK4022","LU0225771236.USD","LU0306807586.USD","BK4158","LU0225284248.USD","BK4585","BK4082","BK4232","LU0321505868.SGD","LU0985481810.HKD","TAP","LU0306806265.USD"],"gpt_icon":1},{"id":"2483555998","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2483555998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483555998?lang=en_us&edition=fundamental","pubTime":"2024-11-16 09:45","pubTimestamp":1731721500,"startTime":"0","endTime":"0","summary":"Voya Investment Management, the asset management business of Voya Financial, Inc. , announced today the distributions on the common shares of five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund , Voya Infrastructure, Industrials and Materials Fund , Voya Asia Pacific High Dividend Equity Income Fund , and Voya Emerging Markets High Dividend Equity Fund .With respect to each Fund, the distribution will be paid on December 16, 2024, to shareholders of record on December 2, 2024. The ex-dividend date is December 2, 2024. The distribution per share for each Fund is as follows:. Voya Asia Pacific High Dividend Equity Income Fund                      $0.065. Voya Global Advantage and Premium Opportunity Fund                      $0.085. The following table sets forth an estimate of the sources of each Fund's October distribution and its cumulative distributions paid this fiscal year to date. Amounts are e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4184","BK4232","IAE","BK4215","IGD","IHD","LU0061475181.USD","NAV","IDE","LU1878469433.USD","R","VOYA","LU0211331839.USD","BK4585","IGA","BK4588","EQR","BK4022"],"gpt_icon":0},{"id":"2483559505","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2483559505","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483559505?lang=en_us&edition=fundamental","pubTime":"2024-11-16 09:44","pubTimestamp":1731721440,"startTime":"0","endTime":"0","summary":"VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION. Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in October 2024. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the November distribution. It is not determinative of the tax character of the Funds' distributions for the 2024 calendar year. Shareholders should note that the Funds' total regular distribution amou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FUND","LU0061475181.USD","NAV","IDE","IGA","BK4184","VOYA","LU1878469433.USD","LU0211331839.USD","ARKG"],"gpt_icon":0},{"id":"2483371030","title":"WiSA Technologies, Inc. Files Preliminary Proxy, Advancing Data Vault Asset Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371030","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371030?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:00","pubTimestamp":1731679200,"startTime":"0","endTime":"0","summary":"- Data Vault’s CEO to join today’s Q3 2024 conference call to discuss its commercialization strategy –。BEAVERTON, Ore., November 15, 2024----WiSA Technologies, Inc. , which is in a definitive agreement to acquire AI, blockchain and Data Web 3.0 IP assets of Data Vault Holdings, Inc.  to form a data technology & licensing company leveraging IP & proprietary HPC software, today filed a Preliminary Proxy Statement for its Annual Meeting, which included information regarding its planned acquisition of Data Vault’s ADIO and Data Vault assets . In its Q3 2024 conference call and presentation today at 8:00 am PT / 11:00 am ET, Data Vault’s CEO Nate Bradley will also be joining to discuss recent news and the commercialization strategy.Launched DVHolo, its hologram product suite, powered by ADIO and developed in partnership with HYPERVSN, renowned for its innovative holographic solutions that provide an immersive, real-time","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KJvfu8F1hBe7MTIDGXj4ZQ--~B/aD0yNjE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7117fd202eea5c7600299645998ff6cc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KJvfu8F1hBe7MTIDGXj4ZQ--~B/aD0yNjE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7117fd202eea5c7600299645998ff6cc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wisa-technologies-inc-files-preliminary-140000959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WISA","IDE","BK4141"],"gpt_icon":1},{"id":"2483717373","title":"Press Release: WiSA Technologies, Inc. Reports Q3 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483717373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483717373?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:15","pubTimestamp":1731676500,"startTime":"0","endTime":"0","summary":"- Increases revenue 240% in Q3 2024 from Q2 2024 -. WiSA Technologies, Inc. , which is in a definitive agreement to acquire AI, blockchain and Data Web 3.0 IP assets of Data Vault Holdings, Inc.  to form a data technology & licensing company leveraging IP & proprietary HPC software, reported third quarter 2024 financial results in its Form 10-Q, which was filed on November 14, 2024. In its conference call and presentation today at 8:00 am PT / 11:00 am ET, WiSA CEO Brett Moyer will discuss the Company's results and provide a general business update.\"In Q3 2024, we delivered 240% sequential revenue growth, driven by both WiSA HT and our new WiSA E IP being in production with a multi-national licensee,\" said Brett Moyer, CEO of WiSA Technologies. \"With WiSA E TX intellectual property now shipping in media boxes with android OS and expected to be in stores for Christmas, we expect to further this momentum with additional design wins and production advancements in 2025. Further leveraging ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","TM","BK4099","BK4555","WISA","BK4585","03160","IDE","BK4141","R","BK4022","BK4588"],"gpt_icon":1},{"id":"2483658008","title":"Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483658008","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483658008?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532500,"startTime":"0","endTime":"0","summary":"Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies. Two Australian Sites Open For Patient Enrollment in Hemopurifier Cancer Trial. SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.During the second quarter, and subsequently, the company advanced its oncology trial efforts in Australia, while implementing cost-cutting measures to streamline operations. Management is pleased to report positive progress on these initiatives, specifically:. Clinical Trials: The first two patients have now been enrolled at the Royal Adelaide Hospital in Adelaide, Australia. Additionally, Pi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xP9CteM8zMY0_9pwo97hUg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/595e59be0e7283e22cffb3f1ff640cb9"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-announces-financial-results-211500908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4082","IDE","BK4568","AEMD"],"gpt_icon":0},{"id":"2483868460","title":"Press Release: Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868460","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868460?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites. Cash and investments at September 30, 2024 of $11.1 million. Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET. SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.Dr. Shakil Aslam, Talphera Chief Medical Officer, added, \"I remain convinced that nafamostat, if approved, will provide the first FDA-approved regional anticoagulant for CRRT, potentially avoiding the risks of systemic anticoagulation that occurs with heparin. After engagement and discussion with numerous clinicians and the NEPHRO investigators, we have identifie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","TM","03160","BK4555","BK4099","TLPH","BK4585","BK4588","BK4007","ARDS","BK4139"],"gpt_icon":0},{"id":"2482002587","title":"AMD Announces Versal Premium Series Gen 2 Enabling New Levels of System Acceleration to Meet the Demands of Data-Intensive Workloads","url":"https://stock-news.laohu8.com/highlight/detail?id=2482002587","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482002587?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:00","pubTimestamp":1731420000,"startTime":"0","endTime":"0","summary":"Extends Versal Gen 2 portfolio with industry's first FPGA devices featuring CXL 3.1 and PCIe Gen6, with LPDDR5X support, for fast connectivity, more efficient data movement, and unlocking more memoryS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979275/0/en/AMD-Announces-Versal-Premium-Series-Gen-2-Enabling-New-Levels-of-System-Acceleration-to-Meet-the-Demands-of-Data-Intensive-Workloads.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","BK4534","LU0719512351.SGD","IE0009356076.USD","LU1803068979.SGD","LU0081259029.USD","LU1951198990.SGD","AMD","IE00B5949003.HKD","LU1923623000.USD","GFS","LU1242518857.USD","BK4566","LU1852331112.SGD","LU2286300806.USD","BK4585","LU0823434583.USD","LU0127658192.USD","LU0823421333.USD","LU1303367103.USD","IE00BMPRXN33.USD","LU2458330169.SGD","LU0823434740.USD","IDE","LU1989764664.SGD","IE00BMPRXR70.SGD","LU1951200564.SGD","BK4512","LU2098885051.SGD","GEN","LU1316542783.SGD","LU1242518931.SGD","BK4532","LU1880398554.USD","BK4554","BK4573","BK4575","LU1880398471.USD","BK4529","LU0979878070.USD","LU0198837287.USD","BK4141","LU0823421416.USD","LU2264538146.SGD","LU0056508442.USD","LU0109392836.USD","LU2054465674.USD","BK4097"],"gpt_icon":1},{"id":"2482087367","title":"InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482087367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482087367?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"–Submitted a Premarket Approval  application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S.–。–Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures–。–Established its Headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in H1 2025, if approved–。Announced that it has submitted a Premarket Approval  application to the U.S. Food and Drug Administration  seeking marketing approval for the CGuard Prime carotid stent system in the U.S.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ppQ1G1C23WS4qq_MTxC81Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a4275cd4d1570a94e15e50c2e3dbb7b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ppQ1G1C23WS4qq_MTxC81Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a4275cd4d1570a94e15e50c2e3dbb7b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inspiremd-reports-third-quarter-2024-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IDE","NSPR","BK4198"],"gpt_icon":0},{"id":"2482568784","title":"Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2482568784","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482568784?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:01","pubTimestamp":1731330060,"startTime":"0","endTime":"0","summary":"Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital. Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies. SAN DIEGO, Nov. 11, 2024 /PRNewswire/ --Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda  or Opdivo  . The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is the incidence of adverse even","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TTjt9CEe6z.ooowceAOYKA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/a6584df642cfb775c4e0f54ac1290019","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TTjt9CEe6z.ooowceAOYKA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/a6584df642cfb775c4e0f54ac1290019"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-reaches-key-milestone-130100832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-reaches-key-milestone-130100832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4234","FPI","BK4082","BK4084","BK4583","IDE","BK4568","AEMD"],"gpt_icon":0},{"id":"2481951313","title":"Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481951313","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481951313?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:05","pubTimestamp":1730927100,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption  as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration . Talphera ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sQPWhDWk5SmY5Z6YVE9dzg--~B/aD02OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/0c55efac9705092c41bfeaacb985f609","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sQPWhDWk5SmY5Z6YVE9dzg--~B/aD02OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/0c55efac9705092c41bfeaacb985f609"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/talphera-host-third-quarter-2024-210500233.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/talphera-host-third-quarter-2024-210500233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","BK4585","IDE","BK4588","BK4007","HST","TLPH"],"gpt_icon":0},{"id":"2481795812","title":"IDE: Hedge Yourself Against Recession Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2481795812","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481795812?lang=en_us&edition=fundamental","pubTime":"2024-11-07 02:10","pubTimestamp":1730916644,"startTime":"0","endTime":"0","summary":"Adam Gault  The Voya Infrastructure Industrials and Materials Fund (NYSE:IDE) is a closed-end fund that investors can purchase as a method of gaining exposure to the high-yielding infrastructure sector. This can be an attractive proposition in certain situations, as many","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/88621226/image_88621226.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4733837-ide-hedge-yourself-against-recession-risks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["IDE"],"gpt_icon":0},{"id":"2481061646","title":"Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481061646","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481061646?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:01","pubTimestamp":1730898060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.Interested parties without internet access or unable to pre-register may dial in by calling:. PARTICIPANT DIAL IN : 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442. All callers should ask for the Aethlon Medical, Inc. conference call.A replay of the call will be available approximately one hour after the end of the call through December 13, 2024. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529  or 1-412-317-0088  or Canada toll free at 1-855-669-9658. The replay conference ID number is 1920733.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of Sect","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C9.ElEoE6TzNDijC6DZTCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/18be20015a562c42dea5e434bb57d5d0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C9.ElEoE6TzNDijC6DZTCw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/18be20015a562c42dea5e434bb57d5d0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-second-130100732.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-release-fiscal-second-130100732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4588","BK4181","BK4218","BK4585","AEMD","BK4082","HST","IDE","BK4568"],"gpt_icon":0},{"id":"2481670118","title":"Press Release: WiSA Technologies, Inc. to Host Third Quarter 2024 Results Conference Call at 8:00 am Pacific Time | 11:00 am Eastern Time on November 15th","url":"https://stock-news.laohu8.com/highlight/detail?id=2481670118","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481670118?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:05","pubTimestamp":1730894700,"startTime":"0","endTime":"0","summary":"WiSA Technologies, Inc. to Host Third Quarter 2024 Results Conference Call at 8:00 am Pacific Time | 11:00 am Eastern Time on November 15th. WiSA Technologies, Inc. , which is in a definitive agreement to acquire assets of Data Vault Holdings, Inc. to form a data technology & licensing company leveraging IP & proprietary HPC software, will host its third quarter 2024 results conference call at 8:00 am PT / 11:00 am ET, on Friday, November 15, 2024.Those without internet access or who wish to dial in may call: 1-833-366-1124 , or 1-412-317-0702 . All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the WiSA Technologies call.A presentation of the Q3 2024 results will be accessible on Friday, November 15, 2024, under the \"Investors\" section of WiSA Technologies' website.Summary of WiSA Technologies & Data Vault Holdings Proposed Asset Purchase. WiSA Technologies, Inc.  is a leading provider of immersive, wireless sound technology","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","HST","BK4588","BK4585","BK4161","IDE","BK4555","BK4232","BK4181","BK4218","BK4141","03160","TM","WISA","BK4099","EML","BK4022"],"gpt_icon":1},{"id":"2480585916","title":"Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2480585916","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480585916?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:57","pubTimestamp":1730728620,"startTime":"0","endTime":"0","summary":"THOR Integrated Device     With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the tre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/04/2974117/0/en/Philips-enrolls-first-patient-in-U-S-clinical-trial-for-innovative-integrated-single-device-to-treat-peripheral-artery-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","PHG","BK4585","BK4588","BK4082"],"gpt_icon":0},{"id":"2479084376","title":"enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2479084376","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479084376?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:35","pubTimestamp":1730378100,"startTime":"0","endTime":"0","summary":"Continued progress toward submission of 5th and final module of FDA premarket approval  application for VenoValve in Q4. GLP study for enVVe transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial mid-2025. Ended the quarter with $48.4 million cash and investments on hand sufficient to fund operations beyond expected regulatory approval of the VenoValve and start of the enVVe pivotal trial. IRVINE, CA / ACCESSWIRE / October 31, 2024 / enVVeno Medical Corporation  , a company setting new standards of care for the treatment of venous disease, today reported financial results for the third quarter 2024.\"We are working diligently to collect and analyze the definitive data that we need to complete our PMA application seeking approval from the FDA for the VenoValve and we look forward to releasing that data to the public,\" commented Robert Berman, CEO of enVVeno Medical. \"We are getting closer to seeing the results from all of the time and effor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rpy.FM3VZ7z3S1GPpX7RHA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/3eac4ed7491156cd1c068fd0320b16c5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rpy.FM3VZ7z3S1GPpX7RHA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/3eac4ed7491156cd1c068fd0320b16c5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/envveno-medical-reports-third-quarter-123500644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IDE","BK4138","NVNO","CVI","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":93}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDE\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"IDE","amount":0.1,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-15"},{"date":"2025-03-03","symbol":"IDE","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-17","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-17"},{"date":"2025-02-03","symbol":"IDE","amount":0.1,"announcedDate":"2025-01-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-03","defaultRemindTime":1738593000000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-18","payableDate":"2025-02-03","currency":"USD","dateTimestamp":1738558800000,"payDate":"2025-02-18"},{"date":"2024-12-30","symbol":"IDE","amount":0.1,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2025-01-15"},{"date":"2024-12-02","symbol":"IDE","amount":0.1,"announcedDate":"2024-11-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-02","defaultRemindTime":1733149800000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-16","payableDate":"2024-12-02","currency":"USD","dateTimestamp":1733115600000,"payDate":"2024-12-16"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDE\",market:\"US\",,,undefined,":[{"executeDate":"2015-07-01","recordDate":"2015-07-06","paymentDate":"2015-07-15","value":0.405,"currency":"USD"},{"executeDate":"2015-10-01","recordDate":"2015-10-05","paymentDate":"2015-10-15","value":0.365,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-15","value":0.365,"currency":"USD"},{"executeDate":"2016-04-01","recordDate":"2016-04-05","paymentDate":"2016-04-15","value":0.365,"currency":"USD"},{"executeDate":"2016-07-01","recordDate":"2016-07-06","paymentDate":"2016-07-15","value":0.365,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDE\",market:\"US\",delay:false,,,undefined,":{}}}